Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinic...(Boersma. Use of the GENius generator an...),Health

Date:9/2/2008

Boersma. "Use of the GENius generator and a single PVAC catheter for mapping, ablating and confirming isolation reduces the risk of complications and streamlines the procedure by eliminating the need for elaborate mapping and imaging technology. And it is quite effective, in that 82% of the patients had no evidence of atrial fibrillation 9 months after their treatment. This is an important finding, since so many patients with paroxysmal atrial fibrillation are visiting their healthcare provider for help."

The second study presented involved patients with permanent or persistent atrial fibrillation (PPAF), a more severe form of the arrhythmia in which the heart's upper chambers consistently beat in a seemingly chaotic way at very high rates. Patients with PPAF do not respond to standard medications, and many of them have to contend with ongoing and sometimes debilitating symptoms.

"Patients with PPAF represent an important but remarkably challenging subset of AF patients. Ablation Frontiers has the only ablation system expressly designed to treat these particular patients," continued Dr. Boersma. "This alone is a real breakthrough."

Fifty-one patients with PPAF were treated at 5 European centers using the GENius generator and PVAC, as well as two other anatomically-designed catheters from Ablation Frontiers -- the Multi-Array Septal Catheter (MASC(TM)) and Multi-Array Ablation Catheter (MAAC(TM)). Ablation therapy restored the heart to normal rhythm in 94% of the patients on the day of the procedure, with an average procedure time of 144 minutes (+/- 44 minutes) following transseptal puncture. Patients were followed for six months with a cumulative efficacy rate of 81%.

These excellent results align with the results presented recently at other leading scientific sessions from several other studies using Ablation Frontiers breakthrough technology.

"We are honored that a physician of Dr. Boersma's caliber and commitment is helping to
'/>"/>

SOURCE Ablation Frontiers, Inc. Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3
Related medicine technology :

1. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
2. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
3. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
4. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
5. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
6. Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective
7. Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients
8. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
9. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
10. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
11. Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients